Emergence of multidrug-resistant non-fermentative gram negative bacterial infection in hospitalized patients in a tertiary care center of Nepal

Santosh Kumar Yadav1,2*, Rajshree Bhujel2, Shyam Kumar Mishra2, Sangita Sharma2 and Jeevan Bahadur Sherchand2

Abstract

Objective: This study was designed for the characterization and establishment of antibiotic susceptibility profiles of non-fermentative gram negative bacteria isolated from hospitalized patients in a tertiary care hospital of Nepal.

Results: A total of 402 non-fermentative gram negative bacteria was isolated in 1486 culture-positive cases from 6216 different clinical samples obtained from hospitalized patients. Among total non-fermentative gram negative bacterial isolates, the highest number was recovered from specimens collected from lower respiratory tract infections (n = 173, 43.0%) of hospitalized patients followed by pus/swab samples (n = 99, 24.6%) and urinary tract infections (n = 49, 12.2%). The most common non-fermentative gram negative bacteria identified were Acinetobacter baumannii (n = 177, 44.0%), Pseudomonas aeruginosa (n = 161, 40.1%) and Burkholderia cepacia complex (n = 33, 8.2%). These bacterial isolates exhibited a higher rate of insusceptibility to beta-lactam antibiotics, fluoroquinolones, and aminoglycosides. On the other hand, all the isolates of P. aeruginosa and A. baumannii were completely susceptible to colistin sulfate and polymyxin B. Among total isolates, 78.1% (n = 314) were multidrug-resistant with a high rate of multidrug-resistant among A. baumannii (91.0%).

Keywords: Acinetobacter baumannii, Hospitalized patients, Multidrug-resistant, Non-fermentative gram negative bacteria, Pseudomonas aeruginosa

Introduction

Non-fermentative gram negative bacteria (NFGNB) are a heterogeneous group of bacteria that includes Pseudomonas species, Acinetobacter species, Burkholderia species, Stenotrophomonas maltophilia, etc. These organisms are omnipresent and may be recovered from various hospital instruments as well as from the body surface of healthcare workers [1]. They can cause a vast variety of infections in hospitalized patients and account for approximately 15% of all gram negative bacterial infections [2]. NFGNB pose significant challenges in health care settings because of their multiple, intrinsic, or acquired antibiotic resistance. The burden of resistance is presumably more due to the higher rate of empirical antimicrobial treatment than with the virulence of particular strains [3]. NFGNB are becoming a threat to health care systems because these bacteria are mainly associated with opportunistic infections in critically ill and immunocompromised patients. The emergence of infections by these organisms along with the rising drug resistance among them warrants close monitoring of the...
antimicrobial susceptibility profile of these organisms [4]. The objective of this study was to characterize NFGNB and determine its antibiotic susceptibility among hospitalized patients.

Main text

Methods

This study was conducted at the department of clinical microbiology of Tribhuvan University Teaching Hospital, Nepal from January 2017 to December 2017. The various specimens collected from hospitalized patients (suspected with infections) were processed for isolation and identification of NFGNB. The lower respiratory tract specimens and body fluid samples were inoculated on chocolate agar (CA) plate, 5% sheep blood agar (BA) plate, and MacConkey agar (MA) plate. Blood samples were initially enriched with Brain Heart Infusion Broth (BHIB) and then subcultured on to the BA and MA plates. Similarly, wound swab, pus, catheter tips, and urine samples were cultured on BA and MA plates. The CA plates were incubated in a CO₂ incubator at 37 °C for 24 h. The BA and MA plates were incubated at 37 °C for 24 h in an aerobic condition [5]. The identification of significant NFGNB isolates that are associated with infections was performed following standard microbiological techniques which involved the morphological appearance of the colonies, Gram’s staining, motility test and a battery of biochemical tests which included oxidase test, sugar fermentation test including triple sugar iron agar, citrate and acetamide utilization test, nitrate reduction test, decarboxylation tests, gelatin liquefaction test, deoxynucleoside test, etc [6].

The susceptibility of bacterial isolates against different antibiotics was determined by the Kirby–Bauer disk diffusion method and minimum inhibitory concentration (MIC) method for some antibiotics. Interpretations of antibiotic susceptibility test results were made according to the guidelines provided by the Clinical and Laboratory Standards Institute (CLSI) (26th Edition) [7]. *Escherichia coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were used as the control organisms for the antibiotic sensitivity test. The isolates resistant to at least one antibiotic in three or more antimicrobial classes were confirmed as multidrug-resistant (MDR) phenotype [5, 8].

The data generated during the study were analyzed by using the SPSS version 16.0 and interpreted according to frequency distribution and percentage.

Results

From a total of 6216 specimens, 1486 (23.9%) showed significant bacterial growth which included 402 NFGNB (27.1% of culture-positive). The isolation rate of NFGNB was highest from lower respiratory tract infection (37.2%) and lowest from urinary tract infection (17.5%). Among the total of 402 NFGNB isolates, 58.5% (n = 235) were isolated from male and 41.5% (n = 167) were from female patients, with male to female ratio 1.41. The highest number of isolates were from the age group 16–32 years (n = 100) and the least number from the age group 49–64 years (n = 66).

From total isolates, nine species of NFGNB were identified which included *Acinetobacter baumannii* (n = 177, 44.0%) followed by *Pseudomonas aeruginosa* (n = 161, 40.1%), *Burkholderia cepacia* complex (n = 33, 8.2%), *A. calcoaceticus* (n = 11, 2.7%), *A. lwoffii* (n = 10, 2.5%), and few other isolates. The majority of *A. baumannii* (n = 82) and *Pseudomonas aeruginosa* (n = 79) were recovered from lower respiratory tract specimens i.e. sputum, bronchoalveolar lavage, and endotracheal aspirates (Table 1).

Table 1 Distribution of non-fermentative gram negative bacteria in different clinical specimens

| NFGNB isolates               | Clinical specimens | LRTS* | Pus/swabs | Urine | Body fluids | Blood | Catheter tips | Total number (%) |
|------------------------------|--------------------|-------|-----------|-------|-------------|-------|---------------|------------------|
| *Acinetobacter baumannii*    |                    | 82    | 49        | 13    | 20          | 10    | 3             | 177 (44.0)       |
| *Acinetobacter calcoaceticus*|                    | 2     | 3         | 3     | 2           | 1     | –             | 11 (2.7)         |
| *Acinetobacter lwoffii*      |                    | –     | 6         | 2     | 2           | –     | –             | 10 (2.5)         |
| *Acinetobacter haemolyticus* |                    | –     | –         | 3     | –           | –     | –             | 3 (0.8)          |
| *Pseudomonas aeruginosa*     |                    | 79    | 37        | 21    | 18          | 4     | 2             | 161 (40.1)       |
| *Pseudomonas stutzeri*       |                    | –     | 1         | –     | –           | 1     | –             | 2 (0.5)          |
| *Burkholderia cepacia complex*|                   | 8     | 2         | 7     | 5           | 9     | 2             | 33 (8.2)         |
| *Stenotrophomonas maltophilia*|                   | 1     | 1         | –     | 1           | 1     | –             | 4 (1.0)          |
| *Sphingobacterium species*   |                    | 1     | –         | –     | –           | –     | –             | 1 (0.2)          |
| **Total number (%)**         |                    | 173   | 99 (24.6) | 49    | 48 (12.2)   | 26    | 7 (1.7)       | 402 (100)        |

* Lower respiratory tract specimens include sputum, bronchoalveolar lavage, and endotracheal aspirate
intensive care unit (ICU) patients, an equal number (21.9%) from each surgical and medical wards followed by orthopedics (6.5%), pediatrics (4.9%), maternity (4.2%) and burn ward (1.5%).

*Acinetobacter baumannii* and *Pseudomonas aeruginosa* showed a low level of sensitivity to most of the commonly tested antibiotics in clinical practice. When results were critically analyzed for the common organisms amongst these we found that *A. baumannii* and *P. aeruginosa* showed resistance to most of the common drugs except polymyxin B and colistin sulfate. *Acinetobacter calcoaceticus*, *A. lwoffii*, *A. haemolyticus*, and *P. stutzeri* showed high sensitivity against the tested antimicrobials. All the isolates of *Burkholderia cepacia* complex and *Stenotrophomonas maltophilia* showed a considerable amount of sensitivity to co-trimoxazole and doxycycline (Table 2). Among total NFGNB isolates, 78.1% were MDR with a high rate among *A. baumannii*, *P. aeruginosa* and *B. cepacia* complex (Table 3).

### Discussion

Infection in hospitalized patients is a global health problem. Despite awareness and hospital care, infections continue to develop in hospitalized patients [9]. Non-fermentative gram negative bacteria were previously considered less significant pathogens but they have now emerged as important nosocomial pathogens [10]. In our study, a total of 402 NFGNB were isolated from hospitalized patients which are 27.1% of culture-positive samples. A similar growth rate of NFGNB was documented by Bhagava et al. (29.6%) [11] from Nepal and Sharma et al. (25.6%) [9] from India while Rahbar et al. [12] reported a positivity rate of only 15% for NFGNB from Iran. These variations in the prevalence of NFGNB in different health

### Table 2 Antibiotic susceptibility profile of non-fermentative gram negative bacterial isolates

| Antimicrobial          | Sensitivity rate of non-fermentative gram negative bacteria (%) |  
|------------------------|---------------------------------------------------------------|  
|                        | *Acinetobacter baumannii (n = 177)*                           | *Pseudomonas aeruginosa (n = 161)*                         |  
|                        | with CLSI                                                    | with CLSI                                                  |  
| Amoxicillin-sulbactam  | 18.6 NT                                                     | NT                                                        | NT                                      |
| Piperacillin           | 6.2 21.7                                                     | NT                                                        | NT                                      |
| Piperacillin-tazobactam| 12.4 38.5                                                    | NT                                                        | NT                                      |
| Cefazidime             | 6.2 13.0                                                     | NT                                                        | 12.1                                    |
| Cefotaxime             | 4.5 NT                                                      | NT                                                        | NT                                      |
| Cefepime               | 6.8 15.5                                                    | NT                                                        | NT                                      |
| Meropenem              | 18.1 38.5                                                   | 66.7                                                      | 66.7                                    |
| Imipenem               | 20.3 42.2                                                   | NT                                                        | NT                                      |
| Ciprofloxacin          | 11.3 12.4                                                   | NT                                                        | NT                                      |
| Ofloxacin              | NT 13.7                                                      | NT                                                        | NT                                      |
| Levofloxacin           | 19.2 23.0                                                   | NT                                                        | 15.2                                    |
| Gentamicin             | 14.1 43.5                                                   | NT                                                        | NT                                      |
| Amikacin               | 20.9 62.7                                                   | NT                                                        | NT                                      |
| Co-trimoxazole         | 4.0 NT                                                      | NT                                                        | 100                                     |
| Doxycycline            | 42.9 NT                                                     | NT                                                        | 72.7                                    |
| Polymyxin B            | 100 100                                                     | NT                                                        | NT                                      |
| Colistin sulfate       | 100 100                                                     | NT                                                        | NT                                      |
| Chloramphenicol        | NT NT                                                       | NT                                                        | 45.5                                    |

*NT* antibiotics not tested/not recommended by CLSI

### Table 3 Multidrug resistance rate in non-fermentative gram negative bacterial isolates

| NFGNB isolates (number of isolates) | MDR in NFGNB |
|-------------------------------------|--------------|
|                                     | Number | Percentage  |
|-------------------------------------|--------|-------------|
| *Acinetobacter baumannii* (n = 177) | 161    | 91.0        |
| *Acinetobacter calcoaceticus* (n = 11) | 4      | 36.4        |
| *Acinetobacter lwoffii* (n = 10)    | 0      | 0           |
| *Acinetobacter haemolyticus* (= 3)  | 0      | 0           |
| *Pseudomonas aeruginosa* (n = 161)  | 118    | 73.3        |
| *Pseudomonas stutzeri* (n = 2)      | 0      | 0           |
| *Burkholderia cepacia* complex (n = 33) | 26     | 78.8        |
| *Stenotrophomonas maltophilia* (n = 4) | 4      | 100         |
| *Sphingobacterium* species (n = 1)  | 1      | 100         |
| Total (N = 402)                    | 314    | 78.1        |
The pattern of NFGNB infections among patients of different wards was evaluated in this study. High prevalence of NFGNB was isolated from patients of intensive care units (39.1%) followed by surgical and medical wards (21.1% each), orthopedic (6.5%), and pediatric (4.9%) wards. Other studies [25, 26] have also reported a higher incidence of NFGNB infection in ICU patients. It is a well-known fact that the infection rates in ICUs are many times higher than elsewhere in hospitals as ICUs are the hub of critically ill patients, who are most vulnerable to opportunistic infections by NFGNB. In our study, the most common NFGNB causing infections in ICU patients were A. baumannii (n = 84, 53.5%) followed by P. aeruginosa (n = 55, 35.0%) and B. cepacia complex (n = 15, 9.6%). Acinetobacter spp. as the commonest NFGNB pathogen in ICU patients was also documented by Parajuli et al. [5] and Mishra et al. [27].

This study showed lower susceptibility of different NFGNB against many antimicrobials with a high multidrug resistance rate. As a consequence of easy access and haphazard use, many antibiotics have decreased their effectiveness in Nepal. Acinetobacter baumannii isolates showed a very low sensitivity rate (<25%) against penicillins, cephalosporins, fluoroquinolones, aminoglycosides, and even carbapenems. They were moderately and highly susceptible to doxycycline (42.9%) and polymyxins (100%), respectively. The resistance rate is higher than the previous results from the same hospital [28]. Parajuli et al. [5] and Shrestha et al. [18] reported similar antibiotic susceptibility profiles among A. baumannii. Xia et al. [29] documented only 15% A. baumannii susceptible to carbapenems. On the other hand, A. calcoaceticus, A. lwofii, and A. haemolyticas were found highly susceptible to common antimicrobials. Pseudomonas aeruginosa isolates were also found to be highly resistant against β-lactams. Among different antibiotics tested, only 13.0% isolates were found to be susceptible to ceftazidime, 15.5% to cefepime, 38.5% to meropenem, 42.2% to imipenem, 12.4% to ciprofloxacin and 23.0% to levofloxacin, while all the isolates were completely susceptible to polymyxin B and colistin sulfate. Fatima et al. [30] and Xie et al. [29] reported a lower resistance rate in P. aeruginosa against beta-lactam antibiotics. Our finding well correlates with the observations of other studies [5, 31, 32]. All the isolates of B. cepacia complex were found susceptible to co-trimoxazole, 72.7% to doxycycline, 66.7% to meropenem, and only 12.1% to cefazidime. A similar pattern of susceptibility was reported by Parajuli et al. [5] among ICU patients.

The MDR rate among A. baumannii was 91.0% which is extensively high. Shrestha et al. [33] and Mishra et al. [28] also reported around 96% and 95% MDR A. baumannii, respectively. We found 73.3% MDR
P. aeruginosa isolates which are higher than those reported by Mishra et al. [34] from Nepal in 2008 (65.9%), Prakash et al. [35] from India in 2014 (31.7%), and Hassuna et al. [36] from Egypt in 2015 (56%). The rate of MDR P. aeruginosa is in an upward trend throughout the world especially in developing countries causing a life-threatening situation. Stenotrophomonas maltophilia is intrinsically resistant to many antibiotics and MDR is common. In this study, all the S. maltophilia was found to be MDR and only 25.0% isolates were susceptible to levofloxacin and chloramphenicol and 50.0% to doxycycline. Sattler et al. [37] reported a similar resistance rate among S. maltophilia.

In this study, polymyxin B and colistin sulfate showed excellent effect against Acinetobacter species and P. aeruginosa isolates. Co-trimoxazole was found effective against B. cepacia complex and S. maltophilia. The antibiotic resistance among these bacteria has dramatically increased in the last decades and pose a significant challenge to effective therapeutic strategies. Menacing a state of low antimicrobial susceptibility among NFGNB associated with these infections is particularly worrisome. Therefore, surveillance of antibiotic susceptibility profiles of these bacteria should be regularly done.

Limitations
We were unable to evaluate the risk factors and outcomes of NFGNB infections in hospitalized patients due to the unavailability of sufficient data. Furthermore, molecular analysis of the resistant phenotypes and genetic mechanism of drug resistance was not determined.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13104-020-05163-6.

Additional file 1: Table S1. Distribution of specimens and growth rate of non-fermentative gram negative bacteria. Table S2. Distribution of non-fermentative gram negative bacteria with the demographic features of patients. Table S3. Ward wise distribution of non-fermentative gram negative bacterial isolates.

Authors’ contributions
SKY: Conceptualization, investigations, statistical analysis, writing an original draft and final version of the manuscript; RB: Conceptualization, investigations, writing-review, and editing; SKM, SS, JBS: Conceptualization, investigations, supervision, writing-review, and editing. All authors read and approved the final manuscript.

Funding
This work was conducted with partial financial assistance from the Nepal Health Research Council (NHRC) (No. 773).

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its additional information files (Additional file 1: Table S1–S3).

Ethics approval and consent to participate
The ethical approval for the study was obtained from the Institutional Review Board of the Institute of Medicine, Kathmandu, Nepal (Ref. No. 262). Written informed consent was obtained from each patient before enrollment and where participants are children (under 16 years old) from their parent or guardian.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Microbiology, Rajarshi Janak University, Janakpur, Nepal. 2 Department of Clinical Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.

Received: 17 March 2020 Accepted: 27 June 2020
Published online: 02 July 2020

References
1. Mellmann A, Bimet F, Bizec C, Borovskaya A, Drake R, Eigner U, et al. High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. J Clin Microbiol. 2009;47:3732–4. https://doi.org/10.1128/JCM.00921-09.
2. Siou C, Vaneechoutte M, Dijkshoorn L, Wei Y, Chen Y, Chang T. Identification of non-fermenting Gram-negative bacteria of clinical importance by an oligonucleotide array. J Med Microbiol. 2009;58:696–605. https://doi.org/10.1099/jmm.0.004606-0.
3. Costa S. Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis. Shock. 2008;30:25–9. https://doi.org/10.1097/SHK.0b013e3181899090.
4. Gautam V, Kumar S, Kaur P, Deepak T, Singhal L, Tewari R, et al. Antimicrobial susceptibility pattern of Burkholderia cepacia complex & Stenotrophomonas maltophilia over six years (2007–2012). Indian J Med Res. 2015;142:492–4. https://doi.org/10.4103/0971-5916.169225.
5. Parajuli NP, Acharya SP, Mishra SK, Parajuli K, Rijal BP, Pokhrel BM. High burden of antimicrobial resistance among gram negative bacteria causing healthcare associated infections in a critical care unit of Nepal. Antimicrob Resist Infect Control. 2017;6:67. https://doi.org/10.1186/s13756-017-0222-z.
6. Isenberg H. Clinical microbiology procedure handbook. 2nd ed. Washington: American Society for Microbiology (ASM); 2007.
7. Performance standards for antimicrobial susceptibility testing. Twenty-sixth informational supplement. CLSI document M100S. 26th ed. Wayne: Clinical and Laboratory Standards Institute, 2016.
8. Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.
9. Sharma D, Vyas N, Sinha P, Mathur A. Non fermentative gram negative bacilli as nosocomial pathogens: identification and antibiotic sensitivity in clinical samples of indoor patients. Nepal J Med Sci. 2014;03:101–5. https://doi.org/10.3126/njms.v3i2.13452.

10. Malini A, Deepa E, Gokul E, Prasad S. Nonfermenting gram-negative bacilli infections in a tertiary care hospital in Kolar, Karnataka. J Lab Physicians. 2009;1:62–6. https://doi.org/10.14209/jlt.2009.2727.59701.

11. Bhargava D, Kar S, Saha M. Prevalence of non-fermentative gram negative bacilli infection in tertiary care hospital in Birgunj, Nepal. Int J Curr Microbiol Appl Sci. 2015;4:301–7.

12. Rahbar M, Mehragan H, Akbari N. Prevalence of drug resistance in nonfermenter gram-negative bacilli. Iran J Pathol. 2010;5:90–6.

13. Benachinimbadi K, Padmavathy M, Malini J, Vineeth B. Prevalence of nonfermenting Gram-negative bacilli and their in vitro susceptibility pattern at a tertiary care teaching hospital. J Sci Soc. 2014;41:162–6. https://doi.org/10.4103/0974-0691.1411206.

14. Nautiyal S, Jauhari S, Goel N, Mahawal B. Current trend of nonfermenting gram-negative bacilli infection in a tertiary care hospital of Eastern India. Indian J Clin Pract. 2013;24:451–5.

15. Bhatnagar R, Kumar S, Bansal G, Mehra S. Identification and antimicrobial susceptibility patterns of non-fermentative gram-negative bacilli. Int J Pharma Res Health Sci. 2014;2:347–51.

16. Sah M, Mishra M, Chhota R, Sancheti J, Rijal B, et al. Nosocomial bacterial infection and antimicrobial resistant pattern in a tertiary care hospital in Nepal. J Inst Med. 2014;36:38–48.

17. Jayapriva S, Lata S, Sumathi G. Nonfermentative gram-negative bacilli characterisation and antibiotic resistant pattern study from a tertiary care hospital. Indian J Basic Appl Med Res. 2014;3:227–32.

18. Shrestha S, Tada T, Shrestha B, Kinkae T, Rijal B, Pokhrel B, et al. Phenotypic characterization of multidrug-resistant Acinetobacter baumannii with special reference to metallo-β-lactamase production from the hospitalized patients in a tertiary care hospital in Nepal. J Infect Dev Ctries. 2019;13:273–7. https://doi.org/10.3855/jidc.124.

19. Samawi M, Khan F, Eldeeb Y, Almaslamani M, Alkhali A, Ghabban W, et al. Acinetobacter infections among adult patients in Qatar: a 2-year hospital-based study. Can J Infect Dis Med Microbiol. 2016;2016:1–5. https://doi.org/10.1155/2016/6873689.

20. Anil C, Shahid R. Antimicrobial susceptibility patterns of Pseudomonas aeruginosa clinical isolates at a tertiary care hospital in Kathmandu, Nepal. Asian J Pharm Clin Res. 2013;6:235–8.

21. Rizq M, Nag F, Raj H, Maity P. Prevalence and susceptibility profiles of nonfermentative bacilli. Iran J Pathol. 2010;5:90–6.

22. Rizq M, Nag F, Raj H, Maity P. Prevalence of antimicrobial resistant patterns of non-fermentative gram-negative bacilli. Iran J Pathol. 2010;5:90–6.

23. Shrestha R, Dahal R, Mishra S, Parajuli K, Rijal B, Sherchand J, et al. Ventilator-associated pneumonia in Tertiary Care Hospital, Maharajgunj, Kathmandu, Nepal. J Inst Med. 2013;35:21–10.

24. Mishra S, Acharya J, Khaliq S, Pervesen S, Jabeen S. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa isolated from patients of lower respiratory tract infections. Springerplus. 2012;1:70. https://doi.org/10.1186/2193-1801-1-70.

25. Ansari S, Dhital R, Shrestha S, Thapa S, Puri R, Chaudhary N, et al. Growing menace of antibacterial resistance in clinical isolates of Pseudomonas aeruginosa in Nepal: an insight of beta-lactamase production. Biomed Res Int. 2016. https://doi.org/10.1155/2016/6437208.

26. Behera B, Mathur P, Das A, Kapil A, Sharma V. An evaluation of four different phenotypic techniques for detection of metallo-β-lactamase producing Pseudomonas aeruginosa. Indian J Med Microbiol. 2008;26:233–7. https://doi.org/10.4103/0255-0857.39587.

27. Shrestha R, Dahal R, Mishra S, Parajuli K, Rijal B, Sherchand J, et al. Ventilator associated pneumonia in Tertiary Care Hospital, Maharajgunj, Kathmandu, Nepal. J Inst Med. 2013;35:21–10.

28. Mishra S, Acharya J, Kattel H, Koirala J, Rijal B, Pokhrel B. Metallo-beta-lactamase producing gram-negative bacterial isolates. J Nepal Health Res Counc. 2012;10:208–13.

29. Prakash V, Mishra P, Premi H, Apoorva W, Dhavan S, Kumar A. Increasing incidence of multidrug resistant Pseudomonas aeruginosa in inpatients of a tertiary care hospital. Int J Res Med Sci. 2014;2:1302–6. https://doi.org/10.45542/2320-6012.jrims20141111.

30. Hassuna N, Mohamed A, Abo-Eleouon S, Rizk H. High prevalence of multidrug-resistant Pseudomonas aeruginosa recovered from infected burn wounds in children. Arch Clin Microbiol. 2015;6:1–7.

31. Tatler C, Mason E, Kaplan S. Metallo-β-lactamase producing gram-negative bacilli. Iran J Pathol. 2010;5:90–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.